172 related articles for article (PubMed ID: 31157254)
1. Baseline serum lactate dehydrogenase level predicts survival benefit in patients with metastatic colorectal cancer receiving bevacizumab as first-line chemotherapy: a systematic review and meta-analysis of 7 studies and 1,219 patients.
Feng W; Wang Y; Zhu X
Ann Transl Med; 2019 Apr; 7(7):133. PubMed ID: 31157254
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory indices as prognostic markers in metastatic colorectal cancer patients treated with chemotherapy plus Bevacizumab.
Passardi A; Azzali I; Bittoni A; Marisi G; Rebuzzi F; Molinari C; Bartolini G; Matteucci L; Sullo FG; Debonis SA; Gallio C; Monti M; Valgiusti M; Muratore M; Rapposelli IG; Ulivi P; Frassineti GL
Ther Adv Med Oncol; 2023; 15():17588359231212184. PubMed ID: 38107830
[TBL] [Abstract][Full Text] [Related]
3. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
Heinemann V; Rivera F; O'Neil BH; Stintzing S; Koukakis R; Terwey JH; Douillard JY
Eur J Cancer; 2016 Nov; 67():11-20. PubMed ID: 27592068
[TBL] [Abstract][Full Text] [Related]
4. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
Wagner AD; Thomssen C; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
[TBL] [Abstract][Full Text] [Related]
5. High VEGF-A level at baseline predicts poor treatment effect of bevacizumab-based chemotherapy in metastatic colorectal cancer: a meta-analysis.
Zhao L; Zhang D; Ma H; Jin M; Huang F; Zhang T
Panminerva Med; 2016 Mar; 58(1):48-58. PubMed ID: 26763741
[TBL] [Abstract][Full Text] [Related]
6. Anti-angiogenic therapies for metastatic colorectal cancer.
Wagner AD; Arnold D; Grothey AA; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2009 Jul; (3):CD005392. PubMed ID: 19588372
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.
Arnold D; Lueza B; Douillard JY; Peeters M; Lenz HJ; Venook A; Heinemann V; Van Cutsem E; Pignon JP; Tabernero J; Cervantes A; Ciardiello F
Ann Oncol; 2017 Aug; 28(8):1713-1729. PubMed ID: 28407110
[TBL] [Abstract][Full Text] [Related]
8. The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials.
Jang HJ; Kim BJ; Kim JH; Kim HS
Oncotarget; 2017 Sep; 8(42):73009-73016. PubMed ID: 29069844
[TBL] [Abstract][Full Text] [Related]
9. The Prognostic and Predictive Value of Carbohydrate Antigen 19-9 in Metastatic Colorectal Cancer Patients with First Line Bevacizumab Containing Chemotherapy.
Jiang C; Liu S; He W; Zhang B; Xia L
J Cancer; 2017; 8(8):1410-1416. PubMed ID: 28638455
[No Abstract] [Full Text] [Related]
10. Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer.
Marmorino F; Salvatore L; Barbara C; Allegrini G; Antonuzzo L; Masi G; Loupakis F; Borelli B; Chiara S; Banzi MC; Miraglio E; Amoroso D; Dargenio F; Bonetti A; Martignetti A; Paris M; Tomcikova D; Boni L; Falcone A; Cremolini C
Br J Cancer; 2017 Jan; 116(3):318-323. PubMed ID: 28081548
[TBL] [Abstract][Full Text] [Related]
11. Initial LDH level can predict the survival benefit from bevacizumab in the first-line setting in Chinese patients with metastatic colorectal cancer.
Yin C; Jiang C; Liao F; Rong Y; Cai X; Guo G; Qiu H; Chen X; Zhang B; He W; Xia L
Onco Targets Ther; 2014; 7():1415-22. PubMed ID: 25143746
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor receptor tyrosine kinase inhibitors versus bevacizumab in metastatic colorectal cancer: A systematic review and meta-analysis.
Lin Z; Yang Y; Huang Y; Liang J; Lu F; Lao X
Mol Clin Oncol; 2015 Jul; 3(4):959-967. PubMed ID: 26171215
[TBL] [Abstract][Full Text] [Related]
13. Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients.
Scartozzi M; Giampieri R; Maccaroni E; Del Prete M; Faloppi L; Bianconi M; Galizia E; Loretelli C; Belvederesi L; Bittoni A; Cascinu S
Br J Cancer; 2012 Feb; 106(5):799-804. PubMed ID: 22315053
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy plus bevacizumab as an optimal first-line therapeutic treatment for patients with right-sided metastatic colon cancer: a meta-analysis of first-line clinical trials.
You XH; Jiang YH; Fang Z; Sun F; Li Y; Wang W; Xia ZJ; Wang XZ; Ying HQ
ESMO Open; 2020 Mar; 4(Suppl 2):. PubMed ID: 32132090
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab in combination with first-line chemotherapy in patients with metastatic colorectal cancer: a meta-analysis.
Hu W; Xu WS; Liao XF; He HJ
Minerva Chir; 2015 Dec; 70(6):451-8. PubMed ID: 26013763
[TBL] [Abstract][Full Text] [Related]
16. Hypertension as a predictive biomarker for efficacy of bevacizumab treatment in metastatic colorectal cancer: a meta-analysis.
Chen C; Sun P; Ye S; Weng HW; Dai QS
J BUON; 2014; 19(4):917-24. PubMed ID: 25536596
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature.
Lombardi P; Rossini D; Crespi V; Germani MM; Bergamo F; Pietrantonio F; Santini D; Allegrini G; Daniel F; Pagani F; Antoniotti C; Zaniboni A; Conca V; Latiano TP; Boccaccino A; Passardi A; Tamburini E; Masi G; Di Maio M; Cremolini C
Cancer Treat Rev; 2022 Feb; 103():102326. PubMed ID: 35016085
[TBL] [Abstract][Full Text] [Related]
18. Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer.
Passardi A; Scarpi E; Tamberi S; Cavanna L; Tassinari D; Fontana A; Pini S; Bernardini I; Accettura C; Ulivi P; Frassineti GL; Amadori D
PLoS One; 2015; 10(8):e0134732. PubMed ID: 26244985
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors for survival with bevacizumab-based therapy in colorectal cancer patients: a systematic review and pooled analysis of 11,585 patients.
Petrelli F; Coinu A; Cabiddu M; Borgonovo K; Lonati V; Ghilardi M; Barni S
Med Oncol; 2015 Feb; 32(2):456. PubMed ID: 25572811
[TBL] [Abstract][Full Text] [Related]
20. Lactate Dehydrogenase Is a Useful Marker for Predicting the Efficacy of Bevacizumab-containing Chemotherapy in Patients With Metastatic Colorectal Cancer.
Shibutani M; Maeda K; Kashiwagi S; Nagahara H; Fukuoka T; Iseki Y; Wang EN; Okazaki Y; Hirakawa K; Ohira M
Anticancer Res; 2021 Jul; 41(7):3535-3542. PubMed ID: 34230149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
